Intellectual Property

Treovir owns the worldwide rights to G207 for all indications.  It's intellectual property portfolio consists of trade secrets, know how, proprietary virus and cell line technologies, regulatory filings and FDA-authorized orphan drug exclusivity for it's lead program. 

FDA Orphan Drug Approvals:  

– Glioma tumors: #2002-1552.  The most common pediatric brain tumor.

– Medulloblastoma – #DRU 2019 – 6824.

– Primitive neuroectodermal tumor (PNET) # DRU 2019 – 6922  


Waters AM, Johnston JM, Reddy AT, Fiveash J, Madan-Swain A, Kachurak K, Bag AK, Gillespie GY, Markert JM, Friedman GK.  Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.  Hum Gene Ther Clin Dev. 2017 Mar;28(1):7-16.


Whisenhunt TR Jr, Rajneesh KF, Hackney JR, Markert JM.  Extended disease-free interval of 6 years in a recurrent glioblastoma multiforme patient treated with G207 oncolytic viral therapy.  Oncolytic Virother. 2015 Jan 30;4:33-8.


Markert JM, Razdan SN, Kuo HC, Cantor A, Knoll A, Karrasch M, Nabors LB, Markiewicz M, Agee BS, Coleman JM, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Weichselbaum RR, Fiveash JB, Gillespie GY.  A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.  Mol Ther. 2014 May;22(5):1048-55.


Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Gillespie GY.  Phase Ib trial of mutant herpes simplex virus G207 inoculated  pre-and post-tumor resection for recurrent GBM.  Mol Ther. 2009 Jan;17(1):199-207.


Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL.  Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.  Gene Ther. 2000 May;7(10):867-74.